Podcasts about target validation

What if it was possible to speed up drug development without having to reinvent the wheel? By repurposing existing drugs, drug hunters are taking a giant step forward towards changing the future of drug discovery. Join our panel of drug hunters to hear how they reinvent previously approved drugs to get a head start towards treating patients. Acknowledgements: Hosted by: Chris GarciaNarrated by: Gina Mullane and Chris Garcia  Special thanks to:  Ian WaddellVad LazariBarbara Killian

CHI interviews Dr. Gabriela Chiosis, Associate Member and Lab Head of Molecular Pharmacology and Chemistry at Memorial Sloan Kettering Cancer Center about the trends, tools and challenges in developing chaperome-based therapeutics. Discussion questions include: 1. How have you seen this field evolve over the past few years? 2. Can you share with us what we have learned from discovery and clinical efforts thus far? 3. What tools have recently been developed, including those from your lab, that are currently advancing drug discovery in this space? 4. What are the remaining challenges surrounding drug discovery and development in this space? What has hindered FDA approvals? 5. You are giving a lecture during the upcoming Chemical Biology for Target Validation meeting, June 10-11 in Boston – part of the World Pharma Congress 2015. What do you hope to convey to attendees during your lecture? 6. Where do you see the greatest opportunities for continued development? For more information visit http://www.Healthtech.com/Chemical-Biology-Proteomics

CHI recently spoke with Dr. Chas Bountra, Head of the Structural Genomics Consortium (SGC), and Professor of Translational Medicine and an Associate Head of Medical Sciences at the University of Oxford. In this podcast, Dr. Bountra discusses how the SGC is impacting drug discovery and their work on developing novel probes, specifically for epigenetic targets. Dr. Bountra also gives a sneak peek into his keynote lecture joining the Structure-Based Drug Design and Chemical Biology for Target Validation meetings, May 22 in Boston.

Professor Chas Bountra explains how new drugs can offer novel treatments for neurodegenerative and gastrointestinal diseases, as well as pain disorders. Professor Chas Bountra is interested in identifying and validating target proteins for drug discovery. Various technologies and strategies have allowed him to progress promising clinical candidates into Phase I, II, III studies, and to market. Drug candidates are first selected by screening compounds capable of binding to a target protein. Those compounds are then tested in various assay systems, healthy volunteers and finally in patients. Academic research excels at defining good target proteins. Pharmaceutical companies then facilitate the transition from basic research to clinical trials, producing new therapies for patients.

Professor Chas Bountra explains how new drugs can offer novel treatments for neurodegenerative and gastrointestinal diseases, as well as pain disorders. Professor Chas Bountra is interested in identifying and validating target proteins for drug discovery. Various technologies and strategies have allowed him to progress promising clinical candidates into Phase I, II, III studies, and to market. Drug candidates are first selected by screening compounds capable of binding to a target protein. Those compounds are then tested in various assay systems, healthy volunteers and finally in patients. Academic research excels at defining good target proteins. Pharmaceutical companies then facilitate the transition from basic research to clinical trials, producing new therapies for patients.

Professor Chas Bountra explains how new drugs can offer novel treatments for neurodegenerative and gastrointestinal diseases, as well as pain disorders. Professor Chas Bountra is interested in identifying and validating target proteins for drug discovery. Various technologies and strategies have allowed him to progress promising clinical candidates into Phase I, II, III studies, and to market. Drug candidates are first selected by screening compounds capable of binding to a target protein. Those compounds are then tested in various assay systems, healthy volunteers and finally in patients. Academic research excels at defining good target proteins. Pharmaceutical companies then facilitate the transition from basic research to clinical trials, producing new therapies for patients.